Barinthus Biotherapeutics (BRNS) Cash & Equivalents (2020 - 2026)

Barinthus Biotherapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $65.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 33.56% year-over-year to $65.9 million; the trailing twelve-month figure through Mar 2026 stood at $65.9 million (down 33.56% YoY), and the FY2025 full-year result was $70.5 million, down 36.33% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $65.9 million, down from $70.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $200.6 million in Q1 2022, with the low at $65.9 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $135.8 million across 5 years, with a median of $123.9 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents advanced 28.64% — and 2025, when it sank 36.33%.
• Barinthus Biotherapeutics' Cash & Equivalents stood at $194.4 million in 2022, then retreated by 17.53% to $160.3 million in 2023, then sank by 30.97% to $110.7 million in 2024, then sank by 36.33% to $70.5 million in 2025, then declined by 6.53% to $65.9 million in 2026.
• The last three Cash & Equivalents figures came in at $65.9 million (Q1 2026), $70.5 million (Q4 2025), and $74.3 million (Q3 2025), per Business Quant data.